Literature DB >> 9929100

Epstein-Barr virus infection in Richter's transformation.

S M Ansell1, C Y Li, R V Lloyd, R L Phyliky.   

Abstract

Chronic lymphocytic leukemia (CLL) may convert to a diffuse large cell lymphoma (Richter's syndrome) over time. In occasional cases of Richter's transformation, Epstein-Barr virus (EBV) has been identified in the lymphoma cells. To evaluate the association of EBV infection with Richter's syndrome, the biopsy specimens and clinical records of 25 patients who were seen at the Mayo Clinic between 1984-1996 were retrospectively evaluated for the presence of EBV by immunoperoxidase staining for expression of EBV latent membrane protein (LMP), as well as the expression of EBV RNA and DNA in the cells by in situ hybridization. Four of the 25 patients showed evidence of EBV in the diffuse large cell lymphoma cells-three patients with a B-cell phenotype were positive for LMP, EBV DNA, and RNA; and one patient with a T-cell phenotype had positive EBV RNA in the large cell lymphoma cells. The Richter's syndrome was treated with combination chemotherapy in 15 patients, three received radiotherapy, three were followed without further therapy after a splenectomy, two died before treatment could be started, and one patient had insufficient follow-up. One patient with evidence of EBV in large cell lymphoma cells was treated with acyclovir as initial therapy. The median survival of EBV-positive patients was three months compared with nine months for EBV-negative patients, but this difference was not statistically significant (P = 0.385). Evidence for EBV infection related to Richter's transformation was present in 16% of the patients in this study and may be associated with a poorer outcome. Primary therapy with acyclovir in one patient did not seem to be beneficial and other therapeutic modalities in patients with EBV-positive Richter's transformation need to be explored.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9929100     DOI: 10.1002/(sici)1096-8652(199902)60:2<99::aid-ajh3>3.0.co;2-t

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  23 in total

Review 1.  Richter's transformation in chronic lymphocytic leukemia.

Authors:  Apostolia-Maria Tsimberidou; Michael J Keating; William G Wierda
Journal:  Curr Hematol Malig Rep       Date:  2007-10       Impact factor: 3.952

Review 2.  Recent advances in the diagnosis and therapy of Richter's syndrome.

Authors:  Ronan Swords; John Bruzzi; Francis Giles
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

3.  Epstein-Barr virus infection and chronic lymphocytic leukemia: a possible progression factor?

Authors:  Riccardo Dolcetti; Antonino Carbone
Journal:  Infect Agent Cancer       Date:  2010-11-22       Impact factor: 2.965

4.  How we treat Richter syndrome.

Authors:  Sameer A Parikh; Neil E Kay; Tait D Shanafelt
Journal:  Blood       Date:  2014-01-13       Impact factor: 22.113

Review 5.  Achieving optimal outcomes in chronic lymphocytic leukaemia.

Authors:  T J Hamblin
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 6.  Salubrious effects of oxytocin on social stress-induced deficits.

Authors:  Adam S Smith; Zuoxin Wang
Journal:  Horm Behav       Date:  2011-12-08       Impact factor: 3.587

Review 7.  Stress-induced immune dysregulation: implications for wound healing, infectious disease and cancer.

Authors:  Jonathan P Godbout; Ronald Glaser
Journal:  J Neuroimmune Pharmacol       Date:  2006-08-10       Impact factor: 4.147

8.  EBV related cerebral lymphoma in a leukemia patient treated with alemtuzumab.

Authors:  B van de Langerijt; J K Doorduijn; K H Lam; M J van den Bent
Journal:  J Neurol       Date:  2010-12-07       Impact factor: 4.849

9.  Secondary Hemophagocytic Lymphohistiocytosis With Epstein-Barr Virus-Associated Transformed Follicular Lymphoma: A Case Report and Literature Review.

Authors:  Huan Xu; Xia Xu; Guohui Cui; Jun Fang; Wanxin Chen; Mei Xue; Runming Jin; Hongbo Chen; Lu Zhang; Yu Hu
Journal:  Front Oncol       Date:  2021-06-25       Impact factor: 6.244

10.  VR09 cell line: an EBV-positive lymphoblastoid cell line with in vivo characteristics of diffuse large B cell lymphoma of activated B-cell type.

Authors:  Ilaria Nichele; Alberto Zamò; Anna Bertolaso; Francesco Bifari; Martina Tinelli; Marta Franchini; Roberta Stradoni; Fiorenza Aprili; Giovanni Pizzolo; Mauro Krampera
Journal:  PLoS One       Date:  2012-12-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.